The FDA has approved niraparib and abiraterone acetate (Akeega, Janssen) plus prednisone for the treatment of certain patients with castration-sensitive prostate cancer (CSPC). Specifically, the ...

Hi. I'm Tim and this is my pronunciation workshop. Here, I'm going to show you how English is really spoken. Come on, let's go inside. You see this? This is my lunch - well, either that, or it's some ...

Hi. I'm Tim and this is my Pronunciation Workshop. Here, I'm going to show you how English is really spoken. Come on, let's go inside. Hey, look at this: a present. All wrapped up in paper. Now, do ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. The AMPLITUDE trial showed a 54% reduction in radiographic ...

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer. The FDA has greenlit niraparib and ...

The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...